ReNeuron Group Plc (LON:RENE)‘s stock had its “corporate” rating reiterated by stock analysts at N+1 Singer in a research report issued to clients and investors on Monday.
ReNeuron Group Plc (LON:RENE) opened at 1.75 on Monday. The company’s 50 day moving average price is GBX 1.74 and its 200 day moving average price is GBX 1.92. ReNeuron Group Plc has a 52-week low of GBX 1.65 and a 52-week high of GBX 3.67. The firm’s market cap is GBX 55.38 million.
About ReNeuron Group Plc
ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).
Receive News & Ratings for ReNeuron Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.